The China in vitro diagnostics (IVD) market was valued at USD 5.5 billion in 2023 and is projected to reach USD 8.4 billion by 2030, expanding at a compound annual growth rate (CAGR) of 6.4% from 2024 to 2030. The market growth is primarily driven by the rising prevalence of chronic and infectious diseases, including diabetes and cancer, which are increasingly common among the growing geriatric population. As the aging demographic is more vulnerable to these conditions, the need for accurate, early-stage diagnosis and continuous disease monitoring has become critical. In vitro diagnostics (IVD) play a vital role in this process, as they enable timely detection and efficient management of such diseases. Consequently, the demand for IVD kits and reagents has grown significantly across hospitals, laboratories, and home-care settings. Moreover, the COVID-19 pandemic further emphasized the essential role of IVD technologies in large-scale testing, diagnosis, and surveillance, thereby accelerating the adoption of molecular and immunodiagnostic tools across China’s healthcare infrastructure.

The rapidly expanding population in China has also led to a proportional increase in healthcare spending, as both the government and private sector continue to invest in medical infrastructure and diagnostics. This surge in healthcare expenditure is expected to further drive the growth of the IVD market, given the crucial importance of early diagnosis in reducing treatment costs, disease burden, and mortality rates. To meet the rising healthcare demands, China has been actively focusing on technological innovation, R&D expansion, and local production capabilities to enhance its IVD ecosystem.

Furthermore, commercialization partnerships and co-marketing agreements have become increasingly common, enabling faster product penetration and market reach. Several global IVD companies are entering the Chinese market through strategic collaborations with domestic players to capitalize on the region’s growing demand for advanced diagnostics. For instance, BGI (Beijing Genomics Institute) has been instrumental in facilitating the commercialization and distribution of innovative diagnostic products in China, supporting both international and local firms in expanding their presence. Such collaborations are not only enhancing market accessibility but also promoting the adoption of cutting-edge diagnostic technologies, making China one of the most dynamic and promising markets in the global IVD landscape.

Key Market Trends & Insights:

• Based on Product: The reagents segment dominated the market with a revenue share of 66% in 2023 and is expected to remain the fastest-growing segment during the forecast period. The instruments segment, which includes analyzers, automated systems, and point-of-care devices, is also anticipated to experience robust growth, supported by technological innovations that improve testing speed, accuracy, and automation efficiency.
• Based on Technology: The immunoassay segment led the market in 2023 with a revenue share of 32%, attributed to its widespread application in detecting infectious diseases, cancer biomarkers, and hormone levels. Meanwhile, the coagulation segment is projected to be the fastest-growing technology segment, driven by increasing cases of cardiovascular and blood-related disorders. The growing emphasis on routine coagulation testing in hospitals and diagnostic centers is also expected to accelerate the segment’s growth.
• Based on Application: The infectious diseases segment accounted for the largest revenue share of 36% in 2023, as the demand for accurate and rapid diagnostic tests continues to increase due to the high prevalence of viral and bacterial infections. Meanwhile, the drug testing segment is projected to grow at the fastest rate, owing to the rising need for drug abuse detection and monitoring, both in clinical and non-clinical settings. The growing awareness regarding substance abuse and the implementation of workplace drug testing programs are further supporting this growth.
• Based on End-use: The hospital segment dominated the market with a revenue share of 43% in 2023, driven by the high number of diagnostic procedures conducted in hospital laboratories and the availability of advanced diagnostic infrastructure. The home-care segment, however, is expected to grow at the fastest CAGR during the forecast period, propelled by the increasing geriatric population, a rising preference for self-testing, and the availability of compact, user-friendly IVD devices. The COVID-19 pandemic accelerated the shift toward decentralized testing, encouraging the adoption of home-based diagnostics for chronic disease management.
• Based on Test Location: The point-of-care (POC) segment dominated the market with a revenue share of 21.76% in 2023, reflecting the increasing use of portable testing devices that deliver quick and accurate results in non-laboratory settings. POC diagnostics have become crucial in emergency and primary care due to their convenience and ability to facilitate rapid clinical decision-making. The home-care segment is also identified as the fastest-growing test location, driven by the same trend toward patient-centric care and technological advancements that allow reliable testing outside traditional healthcare environments.

Order a free sample PDF of the China In Vitro Diagnostics Market Intelligence Study, published by Grand View Research.

Key Companies & Market Share Insights:

Some of the key established players operating in the IVD market include Abbott, Bio-Rad Laboratories, Inc., Sysmex Corporation, and Shanghai Kehua Bio-Engineering Co. Ltd. These companies employ various market expansion strategies such as collaborations, merger & acquisition activities, and partnerships, along with several product launches to expand their services geographically. In addition, the competitive landscape remains intensely dynamic, with companies encountering challenges in launching diagnostic assays and test kits. Various companies are also expanding their facilities in China owing to their growing population and rising demand for early detection of infectious and communicable diseases. For instance, in January 2022, the company announced plans to invest USD 20 million in expanding its Shanghai manufacturing center to meet the growing demand for liquid chromatography and mass spectrometry in China.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

In conclusion, the China in vitro diagnostics (IVD) market is set to experience steady growth, supported by rising incidences of chronic and infectious diseases, an aging population, and increasing awareness of early disease detection. Continuous advancements in diagnostic technologies, such as molecular testing, immunoassays, and point-of-care devices, are enhancing the speed and accuracy of disease diagnosis, further boosting market expansion. Strong government support for healthcare modernization and growing collaborations between domestic and international companies are also accelerating innovation and product availability. Moreover, the increasing adoption of home-care testing and personalized diagnostics reflects a broader shift toward patient-centric healthcare. Overall, the market is expected to maintain a positive growth trajectory, driven by technological progress, expanding healthcare access, and the country’s ongoing focus on improving medical infrastructure.